Boston Cell Standards Announces Landmark CASI-01 Study in Lancet: eBioMedicine Demonstrating That Calibration Transforms Accuracy and Reproducibility in HER2-Low Breast Cancer Testing Boston Cell Standards today unveiled groundbreaking findings from the CASI-01 study, newly published in Lancet: eBioMedicine, marking a…
ChristianaCare Establishes Organoid Core to Power Precision Cancer Treatment ChristianaCare’s Cawley Center for Translational Cancer Research has launched a groundbreaking organoid core—marking the first time such an advanced, patient-specific modeling platform has been established within a community cancer center program…
Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer, Strengthening Clinical Leadership Amid Advancement of Novel Immunomodulatory Programs Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company focused on developing next-generation immunomodulatory therapeutics for patients living with inflammatory…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a novel gene editing platform designed to counteract drug resistance in…
Johnson & Johnson Strengthens Oncology Leadership With $3.05 Billion Acquisition of Halda Therapeutics and Its Next-Generation RIPTAC™ Platform Johnson & Johnson (NYSE: JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a…
New Survey Shows NMIBC Patients Want More Inclusive Care Conversations and Greater Awareness of Emerging Treatment Options A new national survey conducted in the United States by The Harris Poll, commissioned by ImmunityBio, Inc. (NASDAQ: IBRX), has shed light on…
enGene Reports Updated LEGEND Phase 2 Data Showing 62% Complete Response Rate at Six Months for Detalimogene Voraplasmid in BCG-Unresponsive NMIBC enGene Holdings Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated preliminary…
Revvity Launches Next-Generation Somatic Cancer Reference Standards in Collaboration with MDIC and NIST Revvity, Inc. today announced the release of its new, highly characterized Mimix™ Geni™ somatic cancer reference standards, developed in collaboration with the Medical Device Innovation Consortium (MDIC)…
Kardigan Showcases Positive Phase 2 Data for Ataciguat in Moderate Calcific Aortic Valve Stenosis at AHA Scientific Sessions 2025 Kardigan, a cardiovascular-focused biotechnology company working to modernize drug development for heart disease, announced encouraging new Phase 2 results for its…
CrossBridge Bio Awarded “Best Drug Developer” at the 2025 World ADC Awards, Celebrating Breakthrough Innovation in Dual-Payload ADCs CrossBridge Bio, an emerging biopharmaceutical innovator specializing in the development of next-generation dual-payload antibody-drug conjugates (ADCs), announced that it has received the…
Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune disease, has presented…
Northwell Study Offers Nuanced Hope for Long-Term Seizure Reduction in Chronic, Treatment-Resistant Epilepsy For millions of individuals worldwide, epilepsy remains one of the most challenging chronic neurological disorders to manage. Although many patients achieve seizure control through medication, roughly one-third…
